Can-Fite Biopharma (CANF) vs Lunai Bioworks (LNAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Can-Fite Biopharma is the larger company by market cap ($5.8 million vs $5.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | LNAI |
|---|---|---|
| Share price | $1.90 | $1.23 |
| Market cap | $5.76M | $5.58M |
| 1-day change | -5.00% | +9.82% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| EPS (TTM) | $-13.23 | $-61.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $13.28 |
| 52-week low | $1.90 | $0.8757 |
| Distance from 52-week high | -84.68% | -90.74% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +321.05% | — |
| Average volume | 388.00K | 181.21K |
| Shares outstanding | 3.03M | 4.53M |
| Employees | 5 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Lunai Bioworks
LNAI stock →Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
CANF vs LNAI FAQ
Which is bigger, Can-Fite Biopharma or Lunai Bioworks?
Can-Fite Biopharma (CANF) is larger, with a market capitalization of $5.76M compared with $5.58M for Lunai Bioworks (LNAI).
Are Can-Fite Biopharma and Lunai Bioworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.